Delfi Diagnostics is a biotechnology company that is developing a new generation of liquid biopsy tests for the early detection and diagnosis of cancer. Our mission is to enable the timely detection and treatment of cancer, improving patient outcomes.
Delfi's technology is based on a novel approach to liquid biopsy that leverages the power of next-generation sequencing to detect and analyze circulating tumor DNA (ctDNA). Our tests are designed to be highly accurate, sensitive, and cost-effective, making them accessible to a wider range of patients.
Delfi is committed to developing and delivering transformative diagnostic solutions that will change the way cancer is diagnosed and treated.